Semaglutide vs Retatrutide
Reviewed by the BestHealingPeptides Editorial Team ·
Semaglutide is the licensed GLP-1 monoagonist that defined the modern incretin weight-loss category; retatrutide is Eli Lilly's investigational triple GLP-1/GIP/glucagon agonist, which produced 25.0% mean weight loss at 12 mg over 80 weeks in the Phase III TRIUMPH-1 trial (NEJM 2026). Both target the incretin pathway but at fundamentally different scales of receptor coverage and development maturity.
Semaglutide
A long-acting GLP-1 receptor agonist developed by Novo Nordisk, modified from native GLP-1 with aminoisobutyric acid (Aib) at position 8 (DPP-4 resistance) and a C18 fatty diacid moiety on lysine 26 (albumin binding for ~1-week half-life). Licensed in the UK by the MHRA for type-2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous injection and oral tablets). The most clinically significant GLP-1 receptor agonist of the late 2020s.
Retatrutide
An Eli Lilly triple agonist of the GLP-1, GIP, and glucagon receptors — an extension of tirzepatide's dual-agonist mechanism with added glucagon-receptor activation. Phase II results (Jastreboff et al., NEJM 2023) showed 24.2% mean body weight loss over 48 weeks at the 12 mg dose, and the Phase III TRIUMPH-1 trial (Jastreboff et al., NEJM 2026) reported 25.0% at 12 mg over 80 weeks versus 3.9% with placebo. Not approved in any jurisdiction as of 29 October 2026; Eli Lilly has said it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027.
| Aspect | Semaglutide | Retatrutide |
|---|---|---|
| Receptor coverage | GLP-1R monoagonist | GLP-1R + GIPR + GCGR triple-agonist |
| Development stage | Licensed (MHRA/FDA/EMA) | Phase III results reported; further Phase III trials ongoing; not licensed |
| Trade names | Ozempic, Wegovy, Rybelsus | Investigational (no trade name) |
| Pivotal-trial weight loss (separate trials) | 14.9% at 68 weeks (STEP 1, 2.4 mg) | 25.0% at 80 weeks (TRIUMPH-1, 12 mg) |
| Dosing frequency | Weekly subcutaneous | Weekly subcutaneous (trial protocol) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| WADA status | Not on the Prohibited List | Not named; S0 (non-approved substances) may apply |
| Expected regulatory filing | Filed and approved (from 2017) | US submission planned Q1 2027 (Eli Lilly) |
Mechanism
Semaglutide is a mono-agonist at the GLP-1 receptor (GLP-1R), engineered from native GLP-1 through amino-acid substitutions (Aib at position 8, Arg at position 34) and fatty-acid conjugation for albumin binding, giving a plasma half-life supporting weekly subcutaneous dosing. GLP-1R engagement drives glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and produces central-nervous-system appetite suppression through hypothalamic and brainstem GLP-1R populations. Retatrutide extends this pharmacology across three receptors — GLP-1R, GIPR (glucose-dependent insulinotropic polypeptide receptor), and glucagon receptor (GCGR) — as a single molecule with balanced tri-agonist activity. GIPR co-agonism amplifies insulinotropic effects and may attenuate GLP-1R-related nausea; glucagon-receptor agonism increases resting energy expenditure and hepatic fat mobilisation, producing weight loss through an additional pharmacological axis beyond appetite suppression alone.
Weight-loss magnitude and clinical evidence
Semaglutide's landmark STEP obesity trial programme (Wilding et al., NEJM 2021; subsequent STEP-2 through STEP-8 publications) documented mean weight loss of approximately 15% body weight at 68 weeks on 2.4 mg weekly — the largest effect size documented at trial time for any weight-loss medication and the pharmacological benchmark for the incretin class. Retatrutide's Phase II obesity trial (Jastreboff et al., NEJM 2023) documented mean weight loss of approximately 24% body weight at 48 weeks on 12 mg weekly — a larger mean weight loss than reported for semaglutide in STEP 1, although the trials differed in duration and population. In the Phase III TRIUMPH-1 trial (2,339 adults with obesity, 80 weeks; Jastreboff et al., NEJM 2026, PMID 42814954), mean weight loss was 25.0% at 12 mg versus 3.9% with placebo. In TRANSCEND-T2D-2, which Eli Lilly describes as its first Phase 3 trial comparing retatrutide with another incretin medicine (1,298 adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor, open-label, 80 weeks), Eli Lilly reported on 28 October 2026 that retatrutide 9 mg and 12 mg lowered HbA1c by an average of 2.2% versus 1.8% with Ozempic 2 mg, with weight loss of 19.5% (9 mg) and 20.9% (12 mg) versus 9.4% (efficacy estimand). These are company-reported results that have not yet been published in a journal.
Regulatory status and clinical availability
Semaglutide is MHRA-, FDA-, and EMA-licensed under multiple trade names — Ozempic (type-2 diabetes), Wegovy (obesity; injection and tablets), and Rybelsus (oral tablet formulation for diabetes). NHS prescribing is possible under specific eligibility criteria; private prescription is widely available. Retatrutide is not yet licensed anywhere as of 2026 and remains investigational. Eli Lilly has said it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027; no MHRA or EMA submission has been announced. Grey-market retatrutide has emerged in research-chemical channels ahead of licensing; MHRA has issued warnings against such supply. Semaglutide is not on the WADA Prohibited List. Retatrutide is not named on the List; WADA's S0 category covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use, so athletes should check its status with their anti-doping organisation.
Safety profile expectations
Semaglutide's clinical-trial and post-marketing safety profile is well-characterised: gastrointestinal adverse events (nausea, vomiting, diarrhoea) predominate, dose-titration mitigates severity, and pancreatitis and biliary disease are documented but uncommon. Retatrutide's published trial safety data show a broadly similar profile — gastrointestinal effects lead adverse events. Both compounds carry considerations for hepatic disease, retinopathy, and pregnancy, and both require careful monitoring of pancreatic and biliary function. Retatrutide safety beyond the 80-week TRIUMPH-1 trial is not yet established.
Choosing between them (research context)
For registered clinical use as of 2026, semaglutide is the only option — retatrutide is not yet licensed. For research contexts characterising the incretin pathway, semaglutide is the pharmacologically-defined mono-agonist standard and the reference against which multi-agonists are calibrated. For research on triple-agonist pharmacology specifically, retatrutide is the current best-characterised compound. The two are not currently substitutes so much as sequential generations of incretin-pathway therapy.
Verdict
Semaglutide is the licensed GLP-1 monoagonist and the current standard-of-care incretin therapy; retatrutide is an investigational triple GLP-1/GIP/glucagon agonist with published Phase III weight-loss data (TRIUMPH-1) but no marketing authorisation. Only semaglutide is licensed for clinical use today; retatrutide has no marketing authorisation in the UK or elsewhere. Grey-market retatrutide supply carries substantial regulatory and safety risk pending licensing.